Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of September 2021, specifically dated September 7, 2021. The document serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) rather than a periodic financial report.
Key Financial Metrics
The filing does not provide consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics for the company. It details a specific executive compensation transaction:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Type: Cash payment following the vesting of 25% of a Deferred Investment Award.
- Volume: 27,706.968 notional Ordinary Shares.
- Price: £14.788 per share.
- Value: Gross cash payment of £409,730.64 (subject to tax withholding).
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely discloses the vesting event for Mr. L Miels, Chief Commercial Officer, which occurred on September 4, 2021.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a regulatory disclosure of a specific equity award settlement.
Investor Verification Points
- Verify the vesting schedule and terms of the GlaxoSmithKline Deferred Investment Award Programme.
- Confirm the share price of £14.788 used for the calculation against market data for September 4, 2021.
- Note that this transaction resulted in a cash payout rather than the issuance of new shares.